Lupin said the product will be manufactured at companys Pithampur facility In India. According to IQVIA, brexpiprazole tablets (RLD: Rexulti Tablets) had estimated annual sales of $1258 million In the U.S for July 2021.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APis in over 100 markets.
On a consolidated basis, the drug majors net profit soared 404.30% to Rs 548.16 crore on 22.2% jump in net sales to Rs 4,237.39 crore in Q1 FY22 over Q1 FY21.
Powered by Capital Market - Live News